Phospho-p63 (Ser160+Ser162)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 3716R
英文名称Phospho-p63 (Ser160+Ser162)
中文名称磷酸化笔63肿瘤抑制基因抗体
别 名p63 (phospho S160/162); p63 (phospho Ser160/Ser162); p-p63 (Ser160/Ser162); AIS; Amplified in squamous cell carcinoma; B(p51A); B(p51B); p63 Alpha; Chronic ulcerative stomatitis protein; CUSP; DN p63 alpha 1; DNp63; EEC3; Keratinocyte transcription factor; Keratinocyte transcription factor KET; KET; LMS; NBP; OFC8; p40; p51; P51/P63; p53 like transcription factor; p53 related protein; p53-related protein p63; p53CP; p63; P73; p73H; p73L; RHS; SHFM4; TP53CP; TP53L; TP63; TP73; TP73L; Transformation related protein 63; Trp53rp1; Trp63; Tumor protein 63; tumor protein 63 kDa with strong homology to p53; Tumor protein p53-competing protein; Tumor protein p53-like; tumor protein p63; Tumor protein p73; tumor protein p73-like; P63_HUMAN.
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 细胞生物 **学 转录调节因子
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
Phospho-p63 (Ser160+Ser162)抗体交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Horse, Sheep,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量77kDa
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human p63 around the phosphorylation site of Ser160/Ser162:AL(p-S)P(p-S)PA
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-p63 (Ser160+Ser162)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
This gene encodes a member of the p53 family of transcription factors. An animal model, p63 -/- mice, has been useful in defining the role this protein plays in the development and maintenance of stratified epithelial tissues. p63 -/- mice have several developmental defects which include the lack of limbs and other tissues, such as teeth and mammary glands, which develop as a result of interactions between mesenchyme and epithelium. Mutations in this gene are associated with ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3); split-hand/foot malformation 4 (SHFM4); ankyloblepharon-ectodermal defects-cleft lip/palate; ADULT syndrome (acro-dermato-ungual-lacrimal-tooth); limb-mammary syndrome; Rap-Hodgkin syndrome (RHS); and orofacial cleft 8. Both alternative splicing and the use of alternative promoters results in multiple transcript variants encoding different proteins. Many transcripts encoding different proteins have been reported but the biological validity and the full-length nature of these variants have not been determined. [provided by RefSeq, Jul 2008].
Function:
Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge.
Subunit:
Binds DNA as a homotetramer. Isoform composition of the tetramer may determine transactivation activity. Isoforms Alpha and Gamma interact with HIPK2. Interacts with SSRP1, leading to stimulate coactivator activity. Isoform 1 and isoform 2 interact with WWP1. Interacts with PDS5A. Isoform 5 (via activation domain) interacts with NOC2L.
Subcellular Location:
Nucleus.
Tissue Specificity:
Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type isoforms. Isoform 10 is predominantly expressed in skin squamous cell carcinomas, but not in normal skin tissues.
Post-translational modifications:
May be sumoylated.
Ubiquitinated. Polyubiquitination involves WWP1 and leads to proteasomal degradation of this protein.
DISEASE:
Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT syndrome) [MIM:103285]: A form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. ADULT syndrome involves ectrodactyly, syndactyly, finger- and toenail dysplasia, hypoplastic breasts and nipples, intensive freckling, lacrimal duct atresia, frontal alopecia, primary hypodontiaand loss of permanent teeth. ADULT syndrome differs significantly from EEC3 syndrome by the absence of facial clefting. Note=The disease is caused by mutations affecting the gene represented in this entry.
Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) [MIM:106260]: An autosomal dominant condition characterized by congenital ectodermal dysplasia with coarse, wiry, sparse hair, dystrophic nails, slight hypohidrosis, scalp infections, ankyloblepharon filiform adnatum, maxillary hypoplasia, hypodontia and cleft lip/palate. Note=The disease is caused by mutations affecting the gene represented in this entry.
Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3) [MIM:604292]: A form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. It is an autosomal dominant syndrome characterized by ectrodactyly of hands and feet, ectodermal dysplasia and facial clefting. Note=The disease is caused by mutations affecting the gene represented in this entry.
Split-hand/foot malformation 4 (SHFM4) [MIM:605289]: A limb malformation involving the central rays of the autopod and presenting with syndactyly, median clefts of the hands and feet, and aplasia and/or hypoplasia of the phalanges, metacarpals, and metatarsals. Some patients have been found to have mental retardation, ectodermal and craniofacial findings, and orofacial clefting. Note=The disease is caused by mutations affecting the gene represented in this entry.
Limb-mammary syndrome (LMS) [MIM:603543]: Characterized by ectrodactyly, cleft palate and mammary-gland abnormalities. Note=The disease is caused by mutations affecting the gene represented in this entry.
Note=Defects in TP63 are a cause of cervical, colon, head and neck, lung and
Ectodermal dysplasia, Rapp-Hodgkin type (EDRH) [MIM:129400]: A form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Characterized by the combination of anhidrotic ectodermal dysplasia, cleft lip, and cleft palate. The clinical syndrome is comprised of a characteristic facies (narrow nose and small mouth), wiry, slow-growing, and uncombable hair, sparse eyelashes and eyebrows, obstructed lacrimal puncta/epiphora, bilateral stenosis of external auditory canals, microsomia, hypodontia, cone-shaped incisors, enamel hypoplasia, dystrophic nails, and cleft lip/cleft palate. Note=The disease is caused by mutations affecting the gene represented in this entry.
Non-syndromic orofacial cleft 8 (OFC8) [MIM:129400]: A birth defect consisting of cleft lips with or without cleft palate. Cleft lips are associated with cleft palate in two-third of cases. A cleft lip can occur on one or both sides and range in severity from a simple notch in the upper lip to a complete opening in the lip extending into the floor of the nostril and involving the upper gum. Note=The disease is caused by mutations affecting the gene represented in this entry.
Similarity:
Belongs to the p53 family.
Contains 1 SAM (sterile alpha motif) domain.
Gene ID:
8626
Phospho-p63 (Ser160+Ser162)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-p63 (Ser160+Ser162)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 ATP citrate lyase 三磷酸腺柠檬酸裂解酶抗体
合格 COX3 细胞色素C氧化酶亚基3抗体
合格 G protein alpha S/NESP55 G蛋白αS抗体（鸟嘌呤核苷酸结合蛋白Gα s）
合格 合格 Glucagon Receptor 胰高血糖素受体抗体
合格 IDH2 草酰琥珀酸脱羧酶抗体
合格 合格 LKB1 苏氨酸蛋白激酶LKB1抗体
合格 COX1/MTCO1 细胞色素c氧化酶1抗体
合格 合格 NDUFA10 NADH氧化还原酶辅酶10抗体
合格 NDUFA8 NADH脱氢酶α家族8抗体
合格 PDK2 丙酮酸脱氢酶激酶亚型2抗体
合格 合格 SDHA 琥珀酸脱氢酶复合体亚基A抗体
合格 BRCA1 乳腺癌易感基因1抗体
合格 GLUT5 葡萄糖转运蛋白5抗体
合格 GYG2 糖原蛋白2抗体
合格 MDH1 可溶性苹果酸脱氢酶抗体
合格 合格 phospho-AMPK alpha-1 (Thr172) 磷酸化腺苷单磷酸活化蛋白激酶α1抗体
合格 ATG5/APG5L 自噬蛋白5/细胞凋亡的特异性蛋白抗体
合格 ATG16L 自噬相关蛋白16A抗体
合格 合格 phospho-C-Myc(Thr358) 磷酸化致癌基因C-Myc抗体
合格 phospho-p23 (Ser113) 磷酸化端粒酶结合蛋白P23抗体
合格 Carbonate dehydratase IX 碳酸酐酶9抗体
合格 Pancreatic Amylase 胰淀粉酶抗体
合格 PDHB 丙酮酸脱氢酶E1β亚单位抗体
合格 PDHA1 丙酮酸脱氢酶α1抗体
合格 合格 Triosephosphate isomerase 磷酸丙糖异构酶抗体
合格 Ketohexokinase 肝果糖激酶抗体
合格 phospho-PPAR alpha (Ser12) 磷酸化α型-过氧化酶活化增生受体抗体